

Skin and mucosal manifestations of systemic fungal infections

V-J Anttila
MD

Consultant of Infectious Diseases
Helsinki University Central Hospital

Deep fungal infections

- Rare in healthy persons
- Major problem in
 - Immunocompromised patients
 - ☐ Haematological malignancy
 - ☐ Organ or stem cell transplantation
 - ☐ After complicated (abdominal) surgery
 - ☐ After prolonged ICU treatment
 - ☐ AIDS patients

Deep fungal infections

- Challenge to
 - Modern medical diagnostics
 - ☐ Imaging
 - ☐ Sampling for microbiological examinations
 - ☐ Microbiology
 - Therapy
 - ☐ Long term antifungal treatment
 - Adverse effects, interactions
 - costs
 - Prevention
 - ☐ Hospital or environmental acquired infections
 - ☐ HEPA and/or laminar air flow room ventilation
 - ☐ construction works of hospital
 - Patient outcome
 - ☐ High infection related mortality
 - ☐ Often poor prognosis of background disease
 - Economy of health care systems
 - ☐ Daily antifungal cost can reach 1 000 €
 - ☐ Treatment lasts usually months

Superficial vs deep fungal infections

■ Superficial

- Very common
- Chronic
- Easy to diagnose
- Not disabling
- Prognosis of patients good

■ Deep

- Uncommon
- Acute or subacute
- Difficult to diagnose
- Disabling
- Prognosis of patients poor

Deep fungal infections

- Deep Candida infections
 - Candidemia
 - ☐ Immunocompromised patients
 - ☐ After complicated abdominal surgery
 - ☐ After prolonged intensive care treatment
 - Severe burn patients
 - Pancreatitis etc
 - ☐ Broad spectrum antibiotic use and central venous catheter use etc.
 - Deep candida abscess
 - ☐ After abdominal or esophageal surgery
 - Usually with other microbes
 - Candida esophagitis or deep mouth infections
 - ☐ Cancer treatment, AIDS patients
 - Candida endophthalmitis
 - ☐ After Candidemia
 - ☐ Intravenous drug abuse
 - Candida endocarditis
 - ☐ Iv drug abuse, valvular surgery
 - Candida osteomyelitis
 - ☐ After candidemia, operation, iv drug abuse

Skin manifestations of systemic candida infections

(Bae GY et al Int J Dermatol 2004;44:550-555)

■ How common

– 15 % in a study by Bae et al 2004 from Seoul, Korea (1989-2002)

📄 Of blood culture positive cases 19/53 (35,8 %)

📄 **C.tropicalis 12/19**

– **C.tropicalis candidemia 14, 12/14=86 %**

📄 C. Albicans 5/19

– C.albicans candidemia 30, 5/30=17 %

📄 C.glabrata 2/19

– C.glabrata candidemia 3, 2/3= 67 %

■ (1.1.2005-26.5.2007 One case of C.tropicalis candidemia at our Hospital district)

Skin manifestations of systemic candida infections

(Bae GY et al Int J Dermatol 2004;44:550-555)

- Type of Candida skin lesions
 - Multiple, erythematous 4/19
 - Purpuric 15/19
 - Maculopapules, nodules, or plaques
 - From 2 mm to 10 cm
 - 9/19 central pale vesicular or pustular centers
 - ▣ Some necrotic centers
 - 16/19 generalized rash

- Conclusion: skin manifestations are typical signs in *C.tropicalis* Candidemia

Skin manifestations of Aspergillus

- In a review by Denning and Stevens(Rev Infect Dis 1990;12:1147-1201)
 - 29 reported cutaneous cases reported (in sufficient detail) out of 2121 published reports (1.4 % of all cases)
 - ▣ neutropenic 14
 - responders 79 %
 - ▣ non-neutropenic 15
 - responders 80 %
 - better respond than in other forms of aspergillosis

Skin manifestations of Aspergillus

Reviewed by van Burik et al J Clin Microbiol 1998;36:3115-21

- Primary cutaneous aspergillosis
 - skin injury
 - ☐ iv catheter sites
 - ☐ traumatic inoculation
 - ☐ occlusive dressing
 - ☐ burns
 - ☐ surgery
 - secondary
 - ☐ contiguous to the skin
 - ☐ haematogenous spread
- HIV-related cutaneous aspergillosis 10 patients
- Non HIV-infected immunocompromised patients, more common
 - burn victims
 - neonates
 - cancer patients
 - after stem cell transplantation
 - after solid organ transplantation

Skin manifestations of Aspergillus

Reviewed by van Burik et al J Clin Microbiol 1998;36:3115-21

- Otherwise healthy
 - surgical wounds
 - traumatic inoculation
 - by exposure high spore counts such as farming
- **Initial lesions**
 - macules, papules, nodules or plaques
 - hemorrhagic bullae
 - ulcerative nodules
 - purulent lesions in neonates
- **Mirobiology**
 - A.fumigatus most common in HIV patients
 - in non-HIV, non-burn patients A.flavus 44 %, A.fumigatus 26 %
- **A.ustus** 3/ 7 published cases primarily cutaneous (Verweij et al J Clin microbiol 1999; 37:1607-1609)

Epidemiology and outcome of zygomycosis: a review of 929 reported cases by *Roden et al CID* 2005;41:634-53

- Review of all zygomycosis reports in the English-language literature since 1885
- 929 Cases analyzed
 - 65 % male
 - median age 40
 - overall mortality 44 %



Epidemiology and outcome of zygomycosis: a review of 929 reported cases by *Roden et al CID*

2005:41:634-53

- 179/929 (19 %) had cutaneous involvement, mortality 31 %
 - localized 98/176 (56 %)
 - ▣ mortality 10 %
 - deep extension 43/176 (24%)
 - ▣ mortality 26 %
 - disseminated 35/176 (20 %)
 - ▣ mortality 94 %
- Rhizopus species 47 % of all patients
- Mucor species 18 %
- Cunninghamella bertholletiae 7 % etc.

Patient case:oral mucormycosis

- 68 years old male
- Pancytopenia
 - ▣ AML, M2
 - ▣ Idarubicine+Cytarabine induction
 - ▣ Mitoxantrone+etoposide+cytarabine consolidation
 - ▣ B-neut < $0.1 \times 10^9/l$: 54 days
- Cariotic teeth problems

Patient case:oral mucormycosis

- Mucormycosis of the mouth
 - operated, bone involvement evacuated
 - liposomal Amphotericin B
 - healed
- Mucormycosis quite rare in hematological patients
 - therapy: radical operation+ posaconazole ±Amphotericin B

Skin Fusariosis

Dignani and Anaissie Clin microbiol Infect 2004;10(suppl 1):67-75,
Nucci and Anaissie CID 2002;35:909-20

- Second most common mold infection in immunocompromised patients
- Most common *Fusarium* sp
 - *F.solani*
 - *F.oxysporum*
 - *F.moniliforme*
- Skin involvement common
 - Precede fungemia by about 5 days
- Blood culture positive >50 % in disseminated form
- Review of 259 patients
 - 232 (90 %) immunocompromised
 - ☐ Cancer 205, aplastic anemia 15, solid organ transplantation 7
 - 27 (10 %) immunocompetent
 - ☐ Tissue breakdown >70 %

Skin Fusariosis

Dignani and Anaissie Clin microbiol Infect 2004;10(suppl 1):67-75,
Nucci and Anaissie CID 2002;35:909-20

- Immunocompromised
 - Skin lesions 72 %
 - ☐ localized 12 %, disseminated 88 %
 - Immunocompetent
 - skin lesions 52 %
 - ☐ localized 93 %, disseminated 7 %
- Type of skin infection
 - Disseminated papules and nodules 145
 - ☐ Necrotic 87
 - Ecthyma gangrenosum 16
 - Surrounding erythema(target) 16
 - ☐ Without necrosis 58
 - ☐ Cellulitis 2
 - Rapid progression in disseminated forms
- Mortality
 - In patients with disseminated lesions 76 %
 - Local skin lesions 39 %

Cutaneous *Scedosporium apiospermum*

Source: Uenotsuchi et al Acta Der Veneraol 2005;85:156-159

- Case report 65 year-old man with Still disease and a lesion in right hand
- Literature review 1998-2003: 19 cases
 - 18/20 immunocompromised patients
 - 15/20 male, age 18-81 years
 - 5 disseminated , 4/5 died
 - 15 local, 10 cured

Skin and mucosal manifestations of systemic fungal infections

- Rare occurrence
- When occurs, may help the clinician in the diagnosis
 - typical outlook
 - easy to biopsy
 - rapid to diagnose (slide preparate: yeast, mold, aspergillus type, mucor type etc)
- Most cases in immunocompromised patients
- Usually not the only site of infection
- Start antifungal therapy immediately
- If local, consider radical surgery
- Means often poor prognosis to patients
 - typically patients have concomitantly other problems